Literature DB >> 2766869

Treatment of childhood bacterial meningitis with ceftriaxone once daily: open, prospective, randomized, comparative study of short-course versus standard-length therapy.

J Kavaliotis1, S G Manios, A Kansouzidou, V Danielidis.   

Abstract

Fifty-two children were included in this study to evaluate and compare short- versus standard-length ceftriaxone therapy for bacterial meningitis. The duration of the short-course regimens was 4, 6 and 7 days for Neisseria meningitidis, Hemophilus influenzae and Streptococcus pneumoniae, respectively. The standard-length regimens were twice as long. On the basis of a computer-generated randomization list, 26 children were assigned either to the short- or to the standard-treatment regimen. Ceftriaxone was given intravenously once daily in a dose of 60 mg/kg after an initial loading dose of 100 mg/kg. The population characteristics, the severity of disease and the cerebrospinal fluid (CSF) findings were similar in the two study groups at admission. Bacteriological and clinical response were comparable. There were no significant differences in the incidence of neurological complications, prolonged fever (greater than or equal to 10 days), persistent pleocytosis and side effects between the two groups. Hearing loss occurred in 3 patients in the standard-length group and in no patients in the short-course group. Diarrhea was the only side effect and occurred in 14% of the patients. The results of the study indicate that the short-duration regimen was adequate for the treatment of meningitis caused by the three major meningeal pathogens. However, the small number of patients do not justify the adoption of the short-course regimen for all children with meningitis. At present, prolongation of ceftriaxone therapy or discontinuation of the drug under strict clinical observation of the patient should be considered in some cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766869     DOI: 10.1159/000238685

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Use of ceftriaxone during epidemics in patients with suspected meningococcal meningitis.

Authors:  Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 2.  Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis.

Authors:  K Prasad; A Kumar; P K Gupta; T Singhal
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 3.  Pre-admission antibiotics for suspected cases of meningococcal disease.

Authors:  Thambu D Sudarsanam; Priscilla Rupali; Prathap Tharyan; Ooriapadickal Cherian Abraham; Kurien Thomas
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

4.  Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children.

Authors:  Scott L Weiss; Mark J Peters; Waleed Alhazzani; Michael S D Agus; Heidi R Flori; David P Inwald; Simon Nadel; Luregn J Schlapbach; Robert C Tasker; Andrew C Argent; Joe Brierley; Joseph Carcillo; Enitan D Carrol; Christopher L Carroll; Ira M Cheifetz; Karen Choong; Jeffry J Cies; Andrea T Cruz; Daniele De Luca; Akash Deep; Saul N Faust; Claudio Flauzino De Oliveira; Mark W Hall; Paul Ishimine; Etienne Javouhey; Koen F M Joosten; Poonam Joshi; Oliver Karam; Martin C J Kneyber; Joris Lemson; Graeme MacLaren; Nilesh M Mehta; Morten Hylander Møller; Christopher J L Newth; Trung C Nguyen; Akira Nishisaki; Mark E Nunnally; Margaret M Parker; Raina M Paul; Adrienne G Randolph; Suchitra Ranjit; Lewis H Romer; Halden F Scott; Lyvonne N Tume; Judy T Verger; Eric A Williams; Joshua Wolf; Hector R Wong; Jerry J Zimmerman; Niranjan Kissoon; Pierre Tissieres
Journal:  Intensive Care Med       Date:  2020-02       Impact factor: 17.440

5.  Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.

Authors:  K Marhoum el Filali; M Noun; A Chakib; M Zahraoui; H Himmich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.